Overview
No overview information available.
Background
No background information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
Comprehensive Report on Tarlatamab (Imdelltra)
I. Introduction to Tarlatamab (Imdelltra)
A. Overview and Development
Tarlatamab, also known by its development code AMG-757 and marketed under the brand name Imdelltra, is an innovative antineoplastic agent engineered and developed by Amgen.[1] It represents a significant advancement in immunotherapy, specifically as a first-in-class agent targeting Delta-like ligand 3 (DLL3).[1] The development of Tarlatamab has been driven by the critical unmet medical need in treating aggressive hematological malignancies and solid tumors, particularly extensive-stage small cell lung cancer (ES-SCLC), a disease notorious for its rapid progression and limited effective treatment options following initial platinum-based chemotherapy.[5]
The designation of Tarlatamab as a "first-in-class" bispecific T-cell engager (BiTE) targeting DLL3 signifies a novel therapeutic strategy for SCLC.[1] This unique position underscores its potential to significantly alter the treatment landscape for this challenging cancer, provided its efficacy and safety are robustly confirmed in broader patient populations and potentially in earlier lines of therapy. SCLC has long been characterized by poor prognoses and a lack of durable responses to conventional treatments beyond the first line. The introduction of a therapy with a distinct mechanism of action, such as Tarlatamab, offers new hope for patients who have exhausted standard therapeutic avenues.
B. Chemical and Physical Properties
Tarlatamab is a biologic medication with the following identifiers and characteristics:
- DrugBank ID: DB17256 [1]
- CAS Number: 2307488-83-9 [1]
- Type: Biotech; specifically, it is a human monoclonal antibody engineered as a Bi-specific T-cell Engager (BiTE).[1]
- Molecular Formula: C4664H7139N1259O1454S34 [1]
- Molar Mass: Approximately 105202.82 g·mol$^{-1}$ [1]
- Source: Human [1]
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2024/07/18 | Phase 1 | Active, not recruiting |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |